somone uk
Experienced Member
- Reaction score
- 6
due to similarities in their technology this is quite inevitable, but it's confirmed that icx has sold trc to aderans for $200,000
this means not only adreans has access to what was before confidential information but it also means they have ownership of TRC which after all has completed phase 2 of 3 clinical trials.
this could potentially bring HM earlier then we originally thought but it's a matter of time if would actually come any earlier
full story: http://www.intercytex.com/icx/news/rele ... 010-03-18/
this means not only adreans has access to what was before confidential information but it also means they have ownership of TRC which after all has completed phase 2 of 3 clinical trials.
this could potentially bring HM earlier then we originally thought but it's a matter of time if would actually come any earlier
full story: http://www.intercytex.com/icx/news/rele ... 010-03-18/